In the context of a population-based screening program, we aimed to evaluate the major mammographic features and clinicopathological characteristics of breast tumors at diagnosis and the associations between them, focusing on tumors with the worst prognosis. We analyzed cancers diagnosed in a cohort of 645,764 women aged 45-69 years participating in seven population-based screening programs in Spain, between January 1, 2000 and December 31, 2006 and followed up until June 2009. We included all interval cancers and a sample of screen-detected cancers, whether invasive or in situ. We compared tumor-related information and breast density for different phenotypes (Triple-negative (TN), HER2?, Luminal B and Luminal A) in screen-detected and interval cancers. We used Chi-square or Fisher's exact test to compare major mammographic features of invasive versus in situ tumors, of screen-detected versus interval cancers, and of different types of interval cancers. We included 2582 tumors (1570 screen-detected and 1012 interval cancers). There were significant differences in the distribution of most clinicopathological variables between screen-detected and interval cancers. Invasive TN interval tumors were more common than other phenotypes in breasts with low mammographic density; three-quarters of these tumors presented as masses without associated calcifications. HER2? tumors were more common in denser breasts and were associated with calcifications and multifocality. Architectural distortion was more common in Luminal A and Luminal B tumors. Certain radiologic findings are associated with pre-invasive lesions; these differ among invasive tumor phenotypes. We corroborate that TN and HER2? cancers have distinctive appearances also in the context of population-based screening programs. This information can be useful for establishing protocols for diagnostic strategies in screening units.
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Introduction
Breast cancer can present and progress in various ways. Early detection and characterization are essential to ensure optimal treatment. On mammography, the best technique for screening, certain findings (e.g., certain types of calcifications, spiculated masses, or architectural distortion) suggest malignancy and can even be considered markers of poor prognosis [1, 2] . However, findings among tumors vary, and few findings are specific for malignant or premalignant lesions.
On the other hand, breast tumors have different biological profiles called phenotypes. Tumor phenotypes define subgroups of tumors associated with the expression of particular immunohistochemical markers [3] . Recognized phenotypes include the triple-negative subtype (negative for ER, PR, and HER2?), which is associated with aggressive histological features, poor prognosis, unresponsiveness to usual endocrine therapies, and shorter survival. Another phenotype, HER2?, is also associated with poor prognosis. Tumor phenotypes can be identified after immunohistochemical analysis; however, in some cases the mammographic findings could be markers of phenotype and even of the likelihood of regional or distant spread. Recent studies analyzing the mammographic findings in the phenotypes that have the worst prognosis (e.g., triple-negative) appear to show that certain findings are common in these tumors; however, contrary to what would be expected, the findings that are most suspicious for malignancy, such as architectural distortion or spiculated lesions, are uncommon in this group [4] [5] [6] [7] [8] [9] [10] . Most of these studies considered small series at a single center and analyzed mammographic findings together with those of other imaging techniques used in the clinical context. Our group recently reported differences in mammographic density associated with tumor phenotype and presentation in screening or in the interval between planned screenings [11] . To date, the relationship between the most representative mammographic findings and tumor phenotype has not been analyzed in the context of population-based mammography screening programs. For these reasons, this study aimed to evaluate the major mammographic features and clinicopathological characteristics of tumors at diagnosis and the associations between them in a screening program, focusing on the phenotypes with the worst prognosis.
Methods
We analyzed breast cancers diagnosed in a cohort of 645,764 women aged 45-69 years participating in one of seven population-based screening programs carried out in 32 imaging centers in five regions in Spain; women were screened between January 1, 2000 and December 31, 2006 and were followed up until June 2009. In accordance with the European guidelines for Quality Assurance in Mammographic Screening Recommendations [12] , every 2 years women in the target population are sent a letter inviting them to participate in the population-based screening program. This nationwide program achieves the required standards.
The ethics committee of Parc de Salut Mar (CEIC Parc de Salut MAR) approved the protocol for data collection and waived the requirement for specific patient consent because we used retrospective data from screening participants who had previously signed information release documents.
During the study period, 5309 cancers were detected in routine screening mammograms and 1669 emerged as interval cancers (primary tumors diagnosed in the interval between an unremarkable screening mammogram and the next planned screening mammogram). We included both invasive and in situ carcinomas. The analysis included all interval cancers and a sample of cancers detected at screening, as specified in Domingo et al. [11] ; cancers for which the diagnostic mammogram was unavailable were excluded. The final analysis focused on the clinical information and mammographic features of 2582 tumors, 1570 diagnosed at screening and 1012 diagnosed in the interval between screenings.
Three panels consisting of three experienced radiologists classified interval cancers; two radiologists independently reviewed both screening and diagnostic mammograms, and the third decided in cases of discrepant findings. Radiologists blinded to the diagnostic mammogram and histological findings first reviewed screening mammograms. Interval cancers were definitively classified into: true interval cancers (the screening mammogram showed normal or benign results), false negatives (the screening mammogram showed an abnormality suspicious for malignancy), minimal signs (the screening mammogram had detectable but non-specific signs), or occult tumors (the diagnostic mammogram had no abnormalities despite clinical signs). More details of the classification process were reported in a previous study [11] .
We ensured that the site where the minimal signs were identified correlated with the site of the interval cancer. When there was no correlation, the case was considered a true interval cancer.
Mammographic features and clinical variables
Age at diagnosis was calculated from the patient's date of birth and date of the mammogram.
Mediolateral-oblique and craniocaudal views were obtained in both the initial and successive rounds, except in one program. All film mammograms were read by two radiologists, except in two programs. For both interval and screening-detected cancers, one radiologist from each panel evaluated the density of the cancer-free breast using a semiquantitative score and aggregated in four categories using percentages of density, similar to the BI-RADS classification: A Up to 25 %; B 25-50 %; C 50-75 %; D 75-100 % [13] . The same radiologist classified mammographic features at diagnosis into the following mutually exclusive categories: mass only, distortions only, calcifications only, asymmetries, concomitant mass and calcifications, concomitant distortion and calcifications, and others. The radiologist also recorded whether the tumor was multifocal and/or multicentric (focality).
Tumor-related information (histology, grade, size, lymph node involvement, estrogen receptor expression (ER), progesterone receptor expression (PR), HER2 overexpression, and Ki67 status) was obtained from the cancer registries, hospital-based registers, and clinical records. Biomarkers were assessed during the diagnostic process in the hospitals. The criteria for positivity used by each hospital followed international recommendations and their updates throughout the study period [14, 15] . For the purposes of this study, tumors were considered positive for Ki67 when more than 20 % of cells stained positive. For the histological classification, we used the International Classification of Diseases for Oncology, 3rd edition. Histological grade was defined according to the ScarffBloom-Richardson criteria, as modified by Elston [16] .
As in the earlier study published by our group [11] , tumors were classified into four immunophenotypes on the basis of the expression of ER, PR, and HER2: (1) 
Statistical analysis
First, we compared the clinical and radiological characteristics of screen-detected versus interval cancers. Clinical characteristics were tabulated by immunophenotype. We compared the main prognostic factors (tumor size, histological grade, ki67, lymph node involvement), metastases at diagnosis, and breast density between invasive TN, HER2?, Luminal A, and Luminal B tumors. We also analyzed the radiological findings and focality by comparing invasive versus in situ tumors and screen-detected versus interval cancers; furthermore, we compared the radiologic findings in the four types of interval cancers. Finally, we compared the degree of regional invasion in function of tumor size and focality. We used SPSS v.20.0 for all statistical analyses. P values \0.05 on two-sided Chi-square or Fisher's exact test for categorical variables were considered significant.
Results
A total of 2582 tumors were included; of these, 1570 were detected during routine screening and 1012 were interval cancers. Figure 1 shows the tumors included, broken down by detection mode and the availability of information about phenotype. Tumor phenotype was available for 1701 invasive tumors (921 screen-detected and 780 interval) and for 133 in situ tumors (108 screen-detected and 25 interval). Table 1 In the entire sample, the phenotype expressed was Luminal A in 63 % of the tumors, Luminal B in 15.5 %, HER2? in 9.4 %, and TN in 12.3 %. These percentages differed significantly between screen-detected and interval tumors: more interval tumors were TN (15.3 vs 9.9 % in screen-detected tumors) and fewer were Luminal A (58.9 vs 66 %). Table 2 shows the main prognostic factors and mammographic density for the 1701 invasive tumors in function of mode of detection and phenotype. In general, interval tumors were larger than screen-detected tumors. Whereas about one-third of screen-detected tumors measured B10 mm, nearly two-thirds of interval tumors measured C20 mm. Among screen-detected tumors, 12.1 % of HER2? tumors measured[50 mm at detection and among interval cancers, the percentage of tumors measuring [50 mm at detection was higher for TN (12.3 %), HER2? (14.1 %), and Luminal B (18.7 %). Histological grade III and positivity to Ki67 were more frequent in interval cancers. Among both screening-detected and interval cancers, TN and HER2? tumors had higher histological grade and greater Ki67 positivity, whereas Luminal A tumors had the highest percentages of histological grade I and negativity to Ki67. Lymph node involvement at the time of diagnosis was more common in interval (58.6 %) than screen-detected tumors (32.5 %). However, in screen-detected tumors, lymph node involvement was present in nearly 50 % of tumors with HER2? phenotype. Among interval cancers, lymph node involvement at diagnosis was most common (62.8 %) in Luminal B tumors, followed by HER2? (56.1 %). Finally, breast density at mammography was associated with tumor phenotype, but the association was only significant in interval cancers. In this sense, compared to other phenotypes, a greater proportion of TN tumors were found in less dense breasts in interval cancers (45.8 %); only 8.3 % of interval TN and 6.6 % of screendetected TN tumors were found in extremely dense breasts ([75 %). By contrast, Luminal B or even Luminal A interval tumors were more common in extremely dense breasts. Table 3 reports the mammographic findings for all the invasive and in situ tumors classified by phenotype and detection. In general, the distribution of mammographic features was similar among screen-detected and interval invasive cancers. However, some differences between phenotypes, especially in screen-detected tumors but also in interval cancers, merit comment. Invasive TN tumors presented as masses with similar frequency between screen-detected and interval tumors (75 vs 74.1 %, respectively). Among invasive HER2? screen-detected tumors, 41.7 % showed calcifications alone and 15 % calcifications associated with a mass, whereas the findings for in situ HER2? tumors were calcifications alone in 100 %. In invasive HER2? interval tumors, calcifications alone were less common (13.2 %). In both screen-detected and interval invasive Luminal A and Luminal B tumors, apart from masses, architectural distortion was also relatively common (10.4-14.5 %). On the other hand, the percentage of multifocality and/or multicentricity (MM) was similar in screen-detected and interval cancers, and more common in in situ tumors than in invasive ones. Thus, about 18-20 % of invasive tumors were multifocal while over 30 % of the in situ were multifocal. There were some differences in MM between different phenotypes, but this association reached statistical significance only in screen-detected invasive cancers: TN and HER2? tumors had significantly more MM (27 and 27.9 %), whereas Luminal A tumors were the type that presented MM less often (15.2 %).
When we compared the mammographic features and MM for each subtype of invasive interval tumor (true interval versus false-negative versus minimal signs, but not occult tumors) according to phenotype (Table 4) , significant differences between phenotypes in the mammographic features were observed only for the true interval tumors, where the pattern was similar to the invasive interval tumors shown in Table 3 . Nevertheless, calcifications alone or associated with masses were present in more than 46 % of HER2? false negatives. On the other hand, in false negatives, we also found significant differences in MM among phenotypes: 30.8 % of HER2? and 39.3 % of Luminal B had MM, whereas only 6.7 % of the TN and 16.4 % Luminal A had MM. In true interval tumors and those that presented with minimal signs, no significant differences in MM were observed between phenotypes, although MM seemed to be more frequent in HER2? interval tumors with minimal signs. Figure 2 shows lymph node involvement in invasive tumors according to tumor size and MM. In screen-detected tumors, larger size was associated with greater lymph node involvement, and the percentage of lymph node involvement was significantly greater in both screendetected and interval MM tumors measuring more than 20 mm. Lymph node invasion was found in 72.1 % of screen-detected tumors with MM and measuring between 21 and 50 mm.
Discussion
This original nationwide study is one of the first to compare the main mammographic findings in different tumor phenotypes within the context of a population-based breast cancer screening program. The most noteworthy findings were that invasive TN interval tumors are more common than other phenotypes in breasts with low mammographic density (\25 %); three-quarters of these tumors presented as masses without associated calcifications. By contrast, invasive HER2? interval tumors were more common in denser breasts and were associated with calcifications and MM; this was true of both interval and screen-detected tumors, but especially of the latter. Architectural distortion was more common in Luminal A and Luminal B tumors. In the attempt to find useful clues to guide treatment decisions, many studies have analyzed different radiologic findings as possible markers for biologic or clinical traits of tumors; however, few studies have compared these findings among tumor phenotypes. In a recent series of invasive carcinomas, Sun et al. [5] found an association between mammographic findings at the time of diagnosis and the molecular phenotype or other clinical characteristics. They reported that malignant calcifications were more common in HER2? and Luminal B tumors, whereas architectural distortion was more common in TN tumors; our findings in TN tumors differ. Ildefonso et al. [18] analyzed the mammographic findings and prognoses in a series of invasive tumors, finding the worst prognosis in tumors that presented mammographically as distortion or asymmetries in density and in those that had suspicious microcalcifications, without taking the immunophenotype into account.
In our study, distortion was more common in Luminal A and Luminal B tumors.
In fact, TN and HER2? tumors represent an important challenge in the management of breast cancer, given their worse prognosis compared to others such as Luminal A and even Luminal B. Our study corroborates that TN and HER2? tumors have certain radiologic characteristics that differentiate them from other tumor phenotypes. In 2013, Brouckaert et al. [19] analyzed a large series of screendetected tumors and compared their long-term prognosis according to phenotype and other clinical aspects of the tumor, with the aim of identifying tumors that might represent overdiagnosis given their excellent prognosis. Tumor palpability was an independent predictor of poor prognosis, regardless of phenotype and lymph node invasion; the authors surmised that palpability might be related to a high cellular concentration or density and/or fibrosis. This might explain why three-quarters of the invasive TN tumors in our study presented on mammography as a mass [20] reported similar results, noting the significant relationship between TN interval cancer and low mammographic density. In our study, this relationship also appears to exist for screen-detected cancers. Another noteworthy aspect is the frequency of radiologic multifocality and/or multicentricity in screen-detected TN tumors, which in turn was associated with greater lymph node invasion for the same tumor size. These observations make sense in the context of the greater aggressiveness and faster progression of TN tumors [21] . In a recent systematic review, Vera-Badillo et al. [22] found that multifocal and/ or multicentric lesions probably have a worse prognosis, although the authors insist that the results of the studies analyzed were heterogeneous and further studies are necessary to settle this question. Our results regarding HER2? tumors corroborate those reported in Elias et al.'s [4] systematic review of the mammographic findings in 2559 HER2? tumors, in which microcalcifications with or without an associated mass were the finding with the strongest association with HER2? overexpression. Although this review also reported a weak association with very high breast density (BI-RADS 4), the authors did not compare breast density between HER2? tumors and other phenotypes. In our study, invasive HER2? tumors were the least commonly diagnosed tumors in less dense breasts. Although we were able to analyze only a small sample of in situ tumors with an identifiable phenotype, and although calcifications were the most common finding in this type of tumor, it is nevertheless noteworthy that in 100 % of the screen-diagnosed in situ HER2? tumors the only findings were calcifications; this frequency is much higher than in the other phenotypes, even in in situ tumors. Our findings and those of other studies such as the Nurses' Health Study [23] that the HER2? phenotype is more common in in situ tumors than in invasive tumors lend strength to the hypothesis that most HER2? tumors go through a preinvasive stage and that some of them do not evolve into invasive tumors. Furthermore, in true interval HER2? tumors, more aggressive lesions with shorter lead-time, calcifications were less common.
One of the strengths of this study is that it analyzed a nationwide cohort. This made it possible to compare the radiologic appearances of different tumor phenotypes in the context of population-based breast cancer screening programs and to distinguish between tumors diagnosed in routine screening and those diagnosed before the next planned screening. Thus, it includes a large series of TN and HER2? tumors. This study continues in the line of research about different aspects of mammographic screening for breast cancer and goes one step further in the characterization of screen-detected and interval tumors, despite the difficulty of obtaining exhaustive retrospective data. Moreover, the protocolization and centralization of the method of reviewing the images and collecting the data adds robustness to the study. Although patients' age range was defined by the norm in European screening programs, there is no reason to think that the results would have differed in many aspects if the study had included patients outside this range. In fact, some of the studies cited above did not incorporate the entire range of possible ages, either.
Other findings reported elsewhere, such as the appearance of the masses or of the calcifications, or even whether an intraductal component was associated to an invasive tumor and its characteristics [24] , have not been analyzed in the present study because these aspects were outside the scope of our objectives. Finally, the findings might have varied slightly if phenotypes had been classified using another system, such as the most recent markers proposed at the St. Gallen conference [25] , in which some phenotypes are subdivided in function of Ki67 or the percentage of positivity of the other receptors. Nevertheless, this marker was not routinely determined in the years covered by our study, and a broad consensus about these classification systems is still lacking. Moreover, the classification used in the present study is the same one used in earlier publications, and this makes our results easy to compare. The analysis of this large series of tumors diagnosed in the context of population-based screening programs has enabled us to corroborate relations between radiologic findings and clinical and pathological findings. In particular, it has enabled us to confirm the distinctive appearances of the tumors with the worst prognosis, TN and HER2?, which we will now be able to evaluate prospectively. In conclusion, certain radiologic findings are associated with pre-invasive lesions; these differ among invasive tumor phenotypes. In the context of population-based screening programs for breast cancer, this information can be useful for establishing protocols for diagnostic strategies in screening units. Further studies should seek more information about the signs that point to the risk of poor prognosis.
